Medical use of combinations of non-natural semaphorins 3 and antimetabolites

The invention relates to a combination of an antimetabolite and a mutated Semaphorin 3 or a functional fragment thereof and the medicai use of the combination in the treatment of a tumor and/or cancer (in particular a pancreatic tumor and/or cancer). The combination comprises the antimetabolite and the mutated Semaphorin 3 or the functional fragment thereof, wherein the mutated Semaphorin 3 is selected from the group consisting of Semaphorin 3A, Semaphorin 3B, Semaphorin 3C, and Semaphorin 3D, and wherein the mutated Semaphorin 3 or the functional fragment thereof comprises an amino acid sequence CX1X2A3GKD, and wherein the alanine (A3) is replaced by a hydrophilic amino acid; or a fusion protein comprising the mutated Semaphorin 3 or the functional fragment thereof; or a nucleic acid molecule encoding the same. Further, the present invention relates to a pharmaceutical composition or a kit of parts comprising the combination.